After the adverse reactions and cases of thrombosis that occurred after the inoculation of the Johnson & Johnson vaccine, Italy is also thinking of intervening to reshape the vaccine plan. According to some rumors, Italy is moving towards administering Johnson & Johnson to the over 60 population. In other words, it would be the same measure put in place a week ago for AstraZeneca doses. Meanwhile, for 2022, Europe has decided not to renew the existing contracts with AstraZeneca and Johnson & Johnson. In short, a crackdown on viral vector vaccines is expected.
Meanwhile, doctors are also asking institutions to clarify the Johnson & Johnson vaccine. “We are talking about a few cases out of millions of vaccinated but I believe that when pharmacovigilance verifies certain things, further investigation is necessary and it is right to suspend cautiously. This is not good for the vaccination campaign, but what to prefer right now? The answer to this question is unique: there is no hesitation. Aifa and Ema must quickly investigate the dossier and decide ». Francesco Vaia, health director of the Spallanzani Institute in Rome, speaks to Radio Capital about the suspension of the Johnson & Johnson vaccine.